
Opinion|Videos|May 20, 2025
The Use of PARP Inhibitors in Ovarian Cancer
Author(s)Kathleen Moore, MD, MS
PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers.
Advertisement
Episodes in this series

Video content is prompted by the following:
PARP Inhibitors in Ovarian Cancer Treatment
Key Themes:
- Biomarker-directed PARP inhibitor use in frontline treatment
- Current FDA approvals and indications
- Overall survival concerns in platinum-sensitive settings
Notable Insights:
- Current frontline approvals:
- Olaparib monotherapy maintenance for BRCA1/2 mutations after response to platinum
- Olaparib with bevacizumab for HRD-positive tumors
- Niraparib approved for all-comers whose tumors responded to chemotherapy
- Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency.
- The FDA restricted platinum-sensitive setting approvals to BRCA-positive patients only due to concerns about potential survival detriment in non-BRCA populations.
Dr Moore stated: “PARP inhibitors are the first truly targeted therapy to benefit patients with ovarian cancer...transformative in a biomarker selected way” and noted: “Best place to use them is in frontline...there is the chance we are curing more patients. We believe that.”
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement



